G.V. Shivashankar is head of the Laboratory of Nanoscale Biology at Paul Scherrer Institute, Professor of Mechano-Genomics, ETH Zurich and a recognized leader in mechanogenomics with strong expertise in cellular reprogramming.
G.V. Shivashankar is head of the Laboratory of Nanoscale Biology at Paul Scherrer Institute, Professor of Mechano-Genomics, ETH Zurich and a recognized leader in mechanogenomics with strong expertise in cellular reprogramming. The Paul Scherrer Institute PSI and Apollo Health Ventures launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of age-related diseases by reprogramming deregulated processes in cells that causes the detrimental processes underlying many serious diseases of aging that represent a significant health burden. The Paul Scherrer Institute and Apollo Health Ventures will join their resources together with scientific founder G.V. Shivashankar, head of the Laboratory of Nanoscale Biology, Paul Scherrer Institute and Professor of Mechano-Genomics, ETH Zurich, a recognized leader in mechanogenomics with strong expertise in cellular reprogramming. The newly founded entity will initially operate out of the Paul Scherrer Institute, the largest research institute for natural and engineering sciences in Switzerland that serves scientists around the world by accommodating highly complicated experiments in their industry-leading research facilities. Focal Biosciences thereby has access to PSI's key infrastructure and expertise as part of Apollo's venture creation program, "Venture Labs" that sources leading science from scientists and labs in Europe and North America, based on its deep understanding of the biology of aging.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
